Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2022

Equity [Abstract]

Share-Based Compensation Expense

Stock-based compensation expense recognized during the three months ended March 31, 2022 and 2021 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three months ended March 31, 2022 and 2021.

	Three Months Ended March 31,
(In thousands)	2022			2021
Cost of revenue:
Provider	$	317		$	276
Payer & Life Sciences		(12	)		57
Total cost of revenue		305			333
Selling, general and administrative expenses		5,489			2,553
Research and development		1,130			1,068
Total stock-based compensation expense	$	6,924		$	3,954

Share-Based Awards Granted

We granted stock-based awards as follows:

	Three Months Ended March 31, 2022
			Weighted-Average
			Grant Date
(In thousands, except per share amounts)	Shares		Fair Value
Service-based restricted stock units		25	$	19.86
		25	$	19.86